Advanced Filters
noise

Broomall, Pennsylvania Clinical Trials

A listing of Broomall, Pennsylvania clinical trials actively recruiting patient volunteers.

Found 844 clinical trials
C Caroline Crocker, DO

Supraglottic Airway for Resuscitation Trial

This is a hybrid type 3 effectiveness-implementation parallel cluster randomized superiority trial designed to compare two strategies to promote early supraglottic airway (SA) rescue during neonatal resuscitation, with a focus on implementation outcomes.

years of age All Phase N/A
O Oleksiy Svezhenets, MD

Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies

The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.

- 17 years of age All Phase 2/3
A Ana Garzon

PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.

18 - 95 years of age All Phase N/A
C Clara Walling, BA

Transforming Hemodialysis-Related Vascular Access Education

The focus of this study is on vascular access for hemodialysis. This is a randomized clinical trial testing 3 educational approaches to help patients with advanced chronic kidney disease prepare for placement of hemodialysis vascular access. Study participants will each be assigned to one of the 3 approaches: 1) "Education", …

18 years of age All Phase N/A
K Kelli Cook

TVMR With the INNOVALVE System Trial - Early Feasibility Study

Study to evaluate the safety and performance of the INNOVALVE system

18 years of age All Phase N/A
S Sarah Sunshine, MD

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0334). In the present study, we want to study the …

18 years of age All Phase 2
R Rachelle David, BSN,RN

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.

18 years of age All Phase 1
M Meghan Rys, MS, CCRP

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconstitution is slow, increasing the risk of infections. …

- 25 years of age All Phase N/A
R Rosalind M Berkowitz, MD

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10 schizophrenia or schizoaffective disorder patients who are actively smoking and have pre-existing TD while receiving stable doses …

18 - 75 years of age All Phase 4
R Rachel Weyl, BS

Naltrexone in AUD Reward Drinkers

This study is a phase IV, two-arm, randomized, double-blind, placebo-controlled study to assess whether individuals identified as primarily reward drinkers are significantly more likely to reduce heavy drinking if they receive XR-NTX than a matching placebo injection. Study subjects will receive monthly injections of long-acting injectable naltrexone 380 mg (4 …

18 - 65 years of age All Phase 4

Simplify language using AI